Is [18F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?

被引：8

作者：

Brepoels, Lieselot ^{[1
]}

Stroobants, Sigrid ^{[1
]}

机构：

[1] Univ Hosp Gasthuisberg, Div Nucl Med, B-3000 Louvain, Belgium

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2007年 / 21卷 / 05期

关键词：

D O I：

10.1016/j.hoc.2007.07.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) is currently the most accurate and reliable tool for the assessment of response in Hodgkin's lymphoma (HL). FDG-PET is superior to conventional imaging techniques for detection of residual disease at the end of treatment, especially in the presence of a residual mass, a frequent finding in HL. FDG-PET response assessment has also a high predictive value early after the initiation of therapy. However, whether risk-adapted treatment strategies based on FDG-PET may also improve patient outcome remains to be proved.

引用

页码：855 / +

页数：16

共 56 条

[1] Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy [J].

Adams, MJ ;

Lipsitz, SR ;

Colan, SD ;

Tarbell, NJ ;

Treves, ST ;

Diller, L ;

Greenbaum, N ;

Mauch, P ;

Lipshultz, SE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3139-3148

[2] CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS [J].

ARMITAGE, JO ;

WEISENBURGER, DD ;

HUTCHINS, M ;

MORAVEC, DF ;

DOWLING, M ;

SORENSEN, S ;

MAILLIARD, J ;

OKERBLOOM, J ;

JOHNSON, PS ;

HOWE, D ;

BASCOM, GK ;

CASEY, J ;

LINDER, J ;

PURTILO, DT .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :160-164

[3] Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation [J].

Becherer, A ;

Mitterbauer, M ;

Jaeger, U ;

Kalhs, P ;

Greinix, HT ;

Karanikas, G ;

Pötzi, C ;

Raderer, M ;

Dudczak, R ;

Kletter, K .

LEUKEMIA, 2002, 16 (02) :260-267

[4] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group [J].

Bhatia, S ;

Yasui, Y ;

Robison, LL ;

Birch, JM ;

Bogue, MK ;

Diller, L ;

DeLaat, C ;

Fossati-Bellani, F ;

Morgan, E ;

Oberlin, O ;

Reaman, G ;

Ruymann, FB ;

Tersak, J ;

Meadows, AT .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4386-4394

[5] DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE [J].

BLAYNEY, DW ;

LONGO, DL ;

YOUNG, RC ;

GREENE, MH ;

HUBBARD, SM ;

POSTAL, MG ;

DUFFEY, PL ;

DEVITA, VT .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12) :710-714

[6] Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].

Brice, P ;

Bouabdallah, R ;

Moreau, P ;

Divine, M ;

Andre, M ;

Aoudjane, M ;

Fleury, J ;

Anglaret, B ;

Baruchel, A ;

Sensebe, L ;

Colombat, P .

BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26

[7] Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:: prevalence and scan interpretation [J].

Castellucci, P ;

Nanni, C ;

Farsad, M ;

Alinari, L ;

Zinzani, P ;

Stefoni, V ;

Battista, G ;

Valentini, D ;

Pettinato, C ;

Marengo, M ;

Boschi, S ;

Canini, R ;

Baccarani, M ;

Monetti, N ;

Franchi, R ;

Rampin, L ;

Fanti, S ;

Rubello, D .

NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (08) :689-694

[8] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[9] Augmented therapy of extensive Hodgkin's disease: Radiation to known disease or prolongation of induction chemotherapy did not improve survival - Results of a cancer and leukemia group B study [J].

Coleman, M ;

Rafla, S ;

Propert, KJ ;

Glicksman, A ;

Peterson, B ;

Nissen, N ;

Brunner, K ;

Holland, JF ;

Anderson, JR ;

Gottlieb, A ;

Kaufman, T .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03) :639-645

[10] Non-Hodgkin's lymphoma - Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma [J].

Cremerius, U ;

Fabry, U ;

Wildberger, JE ;

Zimny, M ;

Reinartz, P ;

Nowak, B ;

Schaefer, W ;

Buell, U ;

Osieka, R .

BONE MARROW TRANSPLANTATION, 2002, 30 (02) :103-111

← 1 2 3 4 5 6 →